TribLIVE

| Home

 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Mylan to buy drug plant in India

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Daily Photo Galleries

'American Coyotes' Series

Traveling by Jeep, boat and foot, Tribune-Review investigative reporter Carl Prine and photojournalist Justin Merriman covered nearly 2,000 miles over two months along the border with Mexico to report on coyotes — the human traffickers who bring illegal immigrants into the United States. Most are Americans working for money and/or drugs. This series reports how their operations have a major impact on life for residents and the environment along the border — and beyond.

Thursday, Oct. 18, 2012, 12:01 a.m.
 

Mylan Inc. agreed to buy an Indian drug manufacturing plant for about $32.5 million, the Cecil-based company said on Wednesday.

Owned by SMS Pharmaceuticals Ltd., the plant specializes in making cancer medications and the active ingredients for cancer drugs.

“The acquisition of this facility will support several of Mylan's strategic growth drivers, particularly expansion of our institutional business,” the company said in a statement.

Generic drugmaker Mylan's institutional subsidiary sells various pharmaceutical products directly to group purchasing organizations, wholesalers, hospitals, long-term care facilities and other large buyers.

Mylan, through its India-based subsidiary Mylan Laboratories Ltd., operates nine pharmaceutical manufacturing plants in India and China. It acquired the Indian operations in 2007 when it purchased Matrix Laboratories, one of the world's largest producers of active pharmaceutical ingredients.

Mylan expects the deal for the SMS facility to close in the first quarter of next year.

In August, Mylan started commercial operations in India by selling products that treat HIV and AIDS and has said it wants to expand in that country.

Mylan, the world's third-largest generic drugmaker by sales, will report third-quarter financial results next week.

Mylan stock closed at $24.28, up 24 cents.

Alex Nixon is a staff writer for Trib Total Media. He can be reached at 412-320-7928 or anixon@tribweb.com.

Add Alex Nixon to your Google+ circles.

Subscribe today! Click here for our subscription offers.

 

 

 


Show commenting policy

Most-Read Stories

  1. Kang’s 9th-inning home run gives Pirates wild victory over Twins
  2. Pirates notebook: Prospect Tucker unaware of ‘trade’ frenzy
  3. Pirates’ Liriano unaffected by poor last outing against Twins
  4. Rossi: ‘Hockey guy’ Sutter will be missed
  5. School credit ratings a problem for several in Western Pennsylvania
  6. Pregnant woman killed by gunfire in Brighton Heights, other shootings reported in city
  7. New Pens winger Fehr ready for defense-first role
  8. Gameday: Pirates at Twins, July 29, 2015
  9. Steelers’ Wheaton adjusting his game moving to slot receiver
  10. Penguins trade Sutter to Canucks, sign free agent center Fehr
  11. Steelers RB Le’Veon Bell gets suspension, fine reduced